SG10201506840QA - Cytotoxicity-inducing therapeutic agent - Google Patents

Cytotoxicity-inducing therapeutic agent

Info

Publication number
SG10201506840QA
SG10201506840QA SG10201506840QA SG10201506840QA SG10201506840QA SG 10201506840Q A SG10201506840Q A SG 10201506840QA SG 10201506840Q A SG10201506840Q A SG 10201506840QA SG 10201506840Q A SG10201506840Q A SG 10201506840QA SG 10201506840Q A SG10201506840Q A SG 10201506840QA
Authority
SG
Singapore
Prior art keywords
cytotoxicity
therapeutic agent
inducing therapeutic
inducing
agent
Prior art date
Application number
SG10201506840QA
Inventor
Junichi Nezu
Takahiro Ishiguro
Atsushi Narita
Akihisa Sakamoto
Yumiko Kawai
Tomoyuki Igawa
Taichi Kuramochi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to JP2010266760 priority Critical
Priority to JP2011121771 priority
Priority to JP2011238818 priority
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201506840QA publication Critical patent/SG10201506840QA/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46171913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201506840Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303Liver or Pancreas
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG10201506840QA 2010-11-30 2011-11-30 Cytotoxicity-inducing therapeutic agent SG10201506840QA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2010266760 2010-11-30
JP2011121771 2011-05-31
JP2011238818 2011-10-31

Publications (1)

Publication Number Publication Date
SG10201506840QA true SG10201506840QA (en) 2015-10-29

Family

ID=46171913

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013041587A SG190726A1 (en) 2010-11-30 2011-11-30 Cytotoxicity-inducing therapeutic agent
SG10201506840QA SG10201506840QA (en) 2010-11-30 2011-11-30 Cytotoxicity-inducing therapeutic agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013041587A SG190726A1 (en) 2010-11-30 2011-11-30 Cytotoxicity-inducing therapeutic agent

Country Status (22)

Country Link
US (1) US20140112914A1 (en)
EP (2) EP3434767A1 (en)
JP (2) JP6278598B2 (en)
KR (2) KR101960109B1 (en)
CN (2) CN103429737A (en)
AR (1) AR084053A1 (en)
AU (3) AU2011337697B2 (en)
BR (1) BR112013013311A2 (en)
CA (1) CA2819530A1 (en)
DK (1) DK2647707T3 (en)
ES (1) ES2693232T3 (en)
HR (1) HRP20181615T1 (en)
LT (1) LT2647707T (en)
MX (1) MX349057B (en)
PL (1) PL2647707T3 (en)
PT (1) PT2647707T (en)
RU (2) RU2663123C2 (en)
SG (2) SG190726A1 (en)
SI (1) SI2647707T1 (en)
TR (1) TR201815863T4 (en)
TW (2) TW201716443A (en)
WO (1) WO2012073985A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3050963T3 (en) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Process for producing polypeptide by arrangement control
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
MX341921B (en) 2011-02-28 2016-09-07 F Hoffmann-La Roche Ag Antigen binding proteins.
WO2012145714A2 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
PT2748202T (en) * 2011-08-23 2018-10-08 Roche Glycart Ag Bispecific antigen binding molecules
US9587025B2 (en) * 2011-12-19 2017-03-07 The Rockefeller University Non-sialylated anti-inflammatory polypeptides
US9845358B2 (en) * 2011-12-19 2017-12-19 The Rockefeller University Anti-inflammatory polypeptides
CN110256567A (en) 2012-06-27 2019-09-20 弗·哈夫曼-拉罗切有限公司 For selecting and generating the stereotropic method of customization target and application thereof containing at least two different binding entities
CN105722529A (en) * 2013-07-05 2016-06-29 根马布股份公司 Humanized or chimeric CD3 antibodies
CN105121630B (en) 2012-10-03 2018-09-25 酵活有限公司 The method of quantitative heavy chain and light chain polypeptide pair
EP2904004B1 (en) * 2012-10-04 2018-11-21 Research Development Foundation Serine protease molecules and therapies
MX2015003616A (en) 2012-10-08 2015-06-05 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use.
CA2892059A1 (en) * 2012-11-21 2014-05-30 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
BR112015012385A2 (en) 2012-11-28 2019-08-27 Zymeworks Inc isolated antigen binding polypeptide construct, isolated polynucleotide or set of isolated polynucleotides, vector or set of vectors, isolated cell, pharmaceutical composition, use of the construct, method for treating a subject having a disease or disorder or cancer or vascular disease, method for inhibiting, reducing or blocking a signal within a cell, method for obtaining the construct, method for preparing the construct, computer readable storage medium, computer implemented method, and method for producing a bi-antigen binding polypeptide construct. specific
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibodies comprising chimeric constant domains
SG11201504497TA (en) 2013-02-26 2015-09-29 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP3444278A1 (en) * 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
TWI652279B (en) * 2013-11-11 2019-03-01 中外製藥股份有限公司 Antigen-binding molecule containing altered antibody variable region
WO2016076345A1 (en) * 2014-11-11 2016-05-19 中外製薬株式会社 Library of antigen-binding molecules including modified antibody variable region
WO2015095392A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
SI3126395T1 (en) 2014-04-02 2019-10-30 Hoffmann La Roche Multispecific antibodies
WO2015150446A1 (en) 2014-04-02 2015-10-08 F. Hoffmann-La Roche Ag Method for detecting multispecific antibody light chain mispairing
SG11201609370QA (en) * 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
AU2015283704A1 (en) 2014-07-01 2016-12-15 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US9777073B2 (en) * 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
AR101262A1 (en) * 2014-07-26 2016-12-07 Regeneron Pharma Purification platform for bispecific antibodies
EP3174897A1 (en) * 2014-07-29 2017-06-07 F.Hoffmann-La Roche Ag Multispecific antibodies
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
PT3177643T (en) * 2014-08-04 2019-07-05 Hoffmann La Roche Bispecific t cell activating antigen binding molecules
WO2016047722A1 (en) * 2014-09-26 2016-03-31 中外製薬株式会社 Cytotoxicity-inducing therapeutic agent
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
JP2018509933A (en) * 2015-02-16 2018-04-12 ロンザ リミテッドLonza Limited Antibody for drug conjugation with mutated CL and / or CH1
JPWO2016182064A1 (en) * 2015-05-13 2018-03-01 中外製薬株式会社 Multiple antigen-binding molecule fusion, pharmaceutical composition, method for identifying linear epitope, and method for producing multiple antigen-binding molecule fusion
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
WO2016205520A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Humanized and affinity matured antibodies to fcrh5 and methods of use
AU2016321146A1 (en) * 2015-09-08 2018-02-01 Theripion, Inc. ApoA-1 fusion polypeptides and related compositions and methods
EP3150637A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Multispecific antibodies
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
JPWO2017086419A1 (en) * 2015-11-18 2018-08-30 中外製薬株式会社 Method for enhancing humoral immune response
US20180326058A1 (en) 2015-11-18 2018-11-15 Chugai Seiyaku Kabushiki Kaisha Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
CA3011419A1 (en) 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
EA201891749A1 (en) * 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Bispecific constructions of antibodies involving t-cells
TW201735947A (en) 2016-03-14 2017-10-16 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773719A (en) 1966-12-06 1973-11-20 Hoffmann La Roche 2-aminoxy-2'-acyl-acetanilide
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6025165A (en) * 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele with einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
DE69229477D1 (en) 1991-09-23 1999-07-29 Cambridge Antibody Tech Methods for producing humanized antibodies
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council Procedures for producing members of specific binding partners.
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH07503132A (en) 1991-12-17 1995-04-06
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2304786T3 (en) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anti-il-8 human antibodies, derived from immunized xenoratones.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
WO2000018806A1 (en) * 1998-09-25 2000-04-06 Horst Lindhofer Bispecific and trispecific antibodies which specifically react with inducible surface antigens as operational target structures
JP2004511430A (en) * 2000-05-24 2004-04-15 イムクローン システムズ インコーポレイティド Bispecific immunoglobulin-like antigen binding protein and production method
CN1294148C (en) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
KR20080077295A (en) 2001-06-22 2008-08-21 츄가이 세이야꾸 가부시키가이샤 Cell proliferation inhibitors containing anti-glypican 3 antibody
AT328906T (en) * 2002-06-28 2006-06-15 Domantis Ltd Dual specific ligands with increased half time
WO2003104453A1 (en) 2002-06-05 2003-12-18 中外製薬株式会社 Method of constructing antibody
WO2004022595A1 (en) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
JP4477579B2 (en) 2003-01-21 2010-06-09 中外製薬株式会社 Antibody light chain screening method
KR101300545B1 (en) * 2004-07-09 2013-09-02 츄가이 세이야꾸 가부시키가이샤 Anti-Glypican 3 Antibody
DK3050963T3 (en) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Process for producing polypeptide by arrangement control
AU2006256030B2 (en) 2005-06-10 2012-06-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
EP2107115A1 (en) * 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
EP3059246B1 (en) * 2007-09-26 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
WO2009053368A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
DK2274008T3 (en) * 2008-03-27 2014-05-12 Zymogenetics Inc Compositions and Methods for Inhibition of PDGFRBETA and VEGF-A
AU2009241589B2 (en) * 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012503612A (en) * 2008-09-26 2012-02-09 ロシュ グリクアート アクチェンゲゼルシャフト Bispecific anti-EGFR / anti-IGF-1R antibody
KR101736447B1 (en) * 2008-12-09 2017-05-16 젠맵 에이/에스 Human antibodies against tissue factor

Also Published As

Publication number Publication date
RU2013129694A (en) 2015-01-10
KR20190028811A (en) 2019-03-19
CN109160951A (en) 2019-01-08
EP2647707A1 (en) 2013-10-09
CN103429737A (en) 2013-12-04
EP3434767A1 (en) 2019-01-30
JPWO2012073985A1 (en) 2014-05-19
MX349057B (en) 2017-07-07
SG190726A1 (en) 2013-07-31
LT2647707T (en) 2018-11-12
AU2011337697A1 (en) 2013-07-04
PT2647707T (en) 2018-11-15
RU2018126811A3 (en) 2019-05-07
AU2017200999A1 (en) 2017-03-09
BR112013013311A2 (en) 2017-09-19
TWI638833B (en) 2018-10-21
TW201716443A (en) 2017-05-16
JP6278598B2 (en) 2018-02-14
ES2693232T3 (en) 2018-12-10
AU2017200565A1 (en) 2017-02-23
EP2647707B1 (en) 2018-09-12
KR101960109B1 (en) 2019-03-20
CA2819530A1 (en) 2012-06-07
EP2647707A4 (en) 2014-04-30
US20140112914A1 (en) 2014-04-24
TR201815863T4 (en) 2018-11-21
AR084053A1 (en) 2013-04-17
AU2017200999B2 (en) 2019-04-18
JP2018093879A (en) 2018-06-21
PL2647707T3 (en) 2019-02-28
TW201249872A (en) 2012-12-16
AU2011337697B2 (en) 2016-10-27
WO2012073985A1 (en) 2012-06-07
DK2647707T3 (en) 2018-11-19
KR20130130765A (en) 2013-12-02
RU2663123C2 (en) 2018-08-01
MX2013006100A (en) 2013-07-15
HRP20181615T1 (en) 2018-12-14
RU2018126811A (en) 2019-03-13
SI2647707T1 (en) 2018-12-31

Similar Documents

Publication Publication Date Title
AP3107A (en) 5-Alkynyl-pyrimidines
EP2566479A4 (en) Azaindazoles
EP2529658A4 (en) Medical device
EP2377457A4 (en) Medical device
GB201212513D0 (en) Therapeutic agents
AU332056S (en) Inhaler
IL222778D0 (en) Diabetes therapy
EP2547244A4 (en) Combination juicer-blender
EP2542086A4 (en) Compounds and therapeutic uses thereof
BR112013013311A2 (en) cytotoxicity-inducing therapeutic agent
EP2628092A4 (en) Device hardware agent
EP2611496A4 (en) Treatment methods
EP2618878A4 (en) Therapeutic vaporizer
EP2640189A4 (en) 3-deutero-pomalidomide
AP3551A (en) Antiviral therapy
GB201010193D0 (en) Medicinal use
GB201106527D0 (en) Therapeutic apparatus
GB0908957D0 (en) Therapeutic agents
AU337041S (en) Inhaler
PL2531409T3 (en) Can body
AU337358S (en) Inhaler
EP2739144A4 (en) Compounds and therapeutic uses thereof
SG10201509055PA (en) Inhaler
AU337042S (en) Inhaler
EP2551283A4 (en) Anti-allergic agent